PET显像联合CT增强扫描对肝脏原发性肿瘤的诊断价值

Value of pet combined with contrast-enhanceed CT scan in the diagnosis of primary tumors of liver

目的:探讨18F-FDGPET联合CT增强扫描在肝脏原发性肿瘤诊断中的临床价值。方法:选取经穿刺活检组织检查或手术病理检查证实的肝脏原发性肿瘤16例,先行全身18F-FDGPET显像后再行肝脏CT三期增强扫描,将所得结论与病理结果进行对比评价。结果:18F-FDGPET联合CT增强扫描诊断肝脏原发性肿瘤的阳性率为93.7%,单PET显像阳性率为62.5%,单CT增强扫描阳性率为81.2%。结论:PET显像联合CT增强扫描较单独PET显像或CT增强扫描对肝脏原发性肿瘤诊断的敏感性及准确性均有明显的提高,因此PET显像联合CT增强扫描在肝脏原发性肿瘤的诊断中有较高的临床价值。

Objective： To evaluate the clinical value of ^18F-FDG PET combined with eontrast-enhanced CT scan in the diagnosis of the primary tumors of the liver. Methods： 16 eases proved surgically and pathologically were examined with PET and then subjacted to CT with third-phase contrast-enhanced scan, and retrospectively analyzed. Results：The positive rate of ^18F-FDG PET combined with eontrast-enhanced CT scan in diagnosis of the primary tumors of the liver was 93.7%, whereas as the positive rate of FDG scan was 62.5% andCT with third-phase enhanced-contrast scan was 81.2%. Conclusion： PET combined with contrast-enhanced CT scan has more sensitivity and accuracy, than PET or CT contrast-enhanced scan. So, the combination of PET with CT has higher clinical value in the diagnosis of the primary tumors of the liver.